Fungoid Af
4 Topics Found
Undecylenic Acid, Undecylenate Salts, Zincundecate
Undecylenic acid is an organic compound with the formula CH2=CH(CH2)8CO2H. It is an unsaturated fatty acid. It is a colorless oil. Undecylenic acid is mainly used for the production of Nylon-11 and in the treatment of fungal infections of the skin, but it is also a precursor in the manufacture of many pharmaceuticals, personal hygiene products, cosmetics, and perfumes.[1] Salts and esters of undecylenic acid are known as undecylenates. Contents 1 Preparation 2 General comm...
A neighbor died after reaching the tumor stage. ## A neighbor struggled with Mycosis Fungoides a lymphoma and after initial treatment stopped going to oncologists. He reached the tumor stage and died. He said at one point he was treating the plaques with epsom salt. ## Yes, epsom salt would only be a topical treatment and it's not proven to help with such a condition, anyway. This is a T-cell lymphoma, so that means he wasn't doing anything to help with the internal source of the problem. Are there any other questions or concerns? ## There needs to be scientific help for Lupus and drugs to cure the disease and not just a band-aid approach. There is no real diagnostic for lupus.
3 REPLIES
Filed under
Antifungal
Mogamulizumab-kpkc
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[3] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[4] It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refracto...
Drug Index
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[3] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[4] It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refracto...